navdx logo white

The first and only clinically validated circulating TTMV® DNA blood test that aids in the detection of HPV-driven cancer.

A highly accurate, reliable blood test.

NavDx is the first and only clinically validated circulating tumor-tissue–modified HPV (TTMV®) DNA blood test that aids in the detection of HPV-driven cancer.

 

NavDx uses proprietary technology to quantify fragments of circulating TTMV HPV DNA, a unique HPV-driven cancer biomarker that cancer cells shed into the blood. This highly accurate blood test reliably uncovers the presence of HPV+ head and neck cancer across the care continuum.¹˒²˒³

scientist with dna

Clinical utility has been validated in multiple studies for head and neck cancer,¹˒³ and proven in real-world practice.³

Distinguishes TTMV HPV DNA from non-cancerous sources of HPV DNA².

NavDx has ≥95% positive and negative predictive values (PPV and NPV) for active, HPV-driven malignancy¹˒³.

Quicker diagnoses. Improved outcomes.

NavDx lets you optimize clinical management of HPV-driven cancer by:

  • Accurately assessing treatment response
  • Identifying the presence of post-treatment molecular residual disease
  • Conveniently monitoring for recurrence.¹˒³

The easy-to-interpret, actionable NavDx test report helps inform clinical decisions, enabling physicians to treat earlier, which may result in improved outcomes.

doctor with patient physicians

This innovative and accessible blood test for HPV+ cancer helps inform clinical decisions, enabling physicians to intervene earlier, which may result in improved outcomes.¹˒³

Get Started with NavDx


nav dx bottom